Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network

Mantle cell lymphoma (MCL) is challenging to manage, with a median survival of 3–5 years. While intensive strategies are often appropriate for younger patients, these approaches are often not appropriate for older patients. In 2006, we reported our initial results using modified R-hyperCVAD (rituxim...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: KENKRE, VAISHALEE P., LONG, WALTER L., EICKHOFF, JENS C., BLANK, JULES H., McFARLAND, THOMAS A., BOTTNER, WAYNE, REZAZEDEH, HAMIED, WERNDLI, JAE E., BAILEY, HOWARD H., KAHL, BRAD S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3489168/
https://ncbi.nlm.nih.gov/pubmed/21864042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2011.580404
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados